Complement pathway amplifies caspase-11–dependent cell death and endotoxin-induced sepsis severity

Brooke A. Napier,¹ Sky W. Brubaker,¹ Timothy E. Sweeney,²,³ Patrick Monette,⁴ Greggory H. Rothmeier,⁵ Nina A. Gertsvolf,¹ Andreas Puschnik,¹ Jan E. Carette,¹ Purvesh Khatri,²,³ and Denise M. Monack¹

¹Department of Microbiology and Immunology, ²Division of Biomedical Informatics Research, Stanford University School of Medicine, and ³Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA 94305
⁴Department of Biology, Middlebury College, Middlebury, VT 05753
⁵Digital Team, Blue Bottle Coffee, Oakland, CA, 94607

Cell death and release of proinflammatory mediators contribute to mortality during sepsis. Specifically, caspase-11–dependent cell death contributes to pathology and decreases in survival time in sepsis models. Priming of the host cell, through TLR4 and interferon receptors, induces caspase-11 expression, and cytosolic LPS directly stimulates caspase-11 activation, promoting the release of proinflammatory cytokines through pyroptosis and caspase-1 activation. Using a CRISPR-Cas9–mediated genome–wide screen, we identified novel mediators of caspase-11–dependent cell death. We found a complement-related peptidase, carboxypeptidase B1 (Cpb1), to be required for caspase-11 gene expression and subsequent caspase-11–dependent cell death. Cpb1 modifies a cleavage product of C3, which binds to and activates C3aR, and then modulates innate immune signaling. We find the Cpb1–C3–C3aR pathway induces caspase-11 expression through amplification of MAPK activity downstream of TLR4 and Ifnar activation, and mediates severity of LPS-induced sepsis (endotoxemia) and disease outcome in mice. We show C3aR is required for up-regulation of caspase-11 orthologues, caspase-4 and −5, in primary human macrophages during inflammation and that c3ar1 and caspase-5 transcripts are highly expressed in patients with severe sepsis; thus, suggesting that these pathways are important in human sepsis. Our results highlight a novel role for complement and the Cpb1–C3–C3aR pathway in proinflammatory signaling, caspase-11 cell death, and sepsis severity.

INTRODUCTION

Sepsis is defined as the presence of a systemic inflammatory response syndrome (SIRS) caused by infection, and is one of the leading causes of death in intensive care units (ICUs); currently, there are more than 19 million cases of sepsis a year worldwide (Rangel-Frausto et al., 1995; Angus et al., 2001; Funk et al., 2009; Angus and van der Poll, 2013). Although the mechanism is not clear, SIRS and an associated infection can develop into severe sepsis, a robust and uncontrollable inflammatory response, which can lead to septic shock and subsequent death (Cerra, 1985; Angus and van der Poll, 2013). Multiple proinflammatory reactions are thought to contribute to the severity of sepsis pathologies (Angus and van der Poll, 2013). These overlapping proinflammatory responses create a complex biological scenario with built-in redundancies, making it difficult to study. Additionally, the proinflammatory pathways that contribute to sepsis have not been fully defined, which compounds the difficulty in developing efficacious diagnostics and therapeutics. Therefore, a better understanding of the molecular pathways that contribute to pathogenesis of sepsis is crucial for the development of more effective diagnostics and therapeutic strategies and in reducing mortality.

Cell death coincides with the production of proinflammatory cytokines, which in turn are associated with poor outcome in patients with sepsis (Ayala et al., 1996; Hotchkiss et al., 1997, 1999, 2003; Isogai et al., 1998; Oberholzer et al., 2001; van der Poll and Opal, 2008). Specifically, the caspase-11–dependent cell death pathway has been shown by multiple groups to exacerbate pathologies in an LPS-induced sepsis mouse model (Kayagaki et al., 2011, 2013; Hagar et al., 2013). Caspase-11 is a cytosolic pattern recognition receptor (PRR) that plays a critical role in responding to cytosolic LPS during Gram-negative bacterial infection and sepsis (Kayagaki et al., 2011, 2013; Aachoui et al., 2013; Hagar et al., 2013). In multiple cell types, caspase-11 expression is induced after initial detection of LPS by TLR4, through Myd88, TRIF, and interferon signaling pathways (Broz and Monack, 2011; Kayagaki et al., 2011; Rathinam et al., 2012; Hagar et al., 2013). Caspase-11 is produced as a monomeric zymogen BMDM, murine BM–derived macrophage; Cpb1, carboxypeptidase B1; CTB, cholera toxin B subunit; gRNA, guide RNA; MDMs, primary human-derived macrophage; pt, post-treatment; qRT–PCR, quantitative RT–PCR; SIRS, systemic inflammatory response syndrome.

Correspondence to Denise M. Monack: dmonack@stanford.edu

Abbreviations used: BMDM, murine BM–derived macrophage; Cpb1, carboxypeptidase B1; CTB, cholera toxin B subunit; gRNA, guide RNA; MDMs, primary human-derived macrophage; pt, post-treatment; qRT–PCR, quantitative RT–PCR; SIRS, systemic inflammatory response syndrome.

© 2016 Napier et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/.

Supplemental Material can be found at: /content/suppl/2016/09/22/jem.20160027.DC1.html
that dimerizes and activates upon detection of cytosolic LPS (Kang et al., 2000). Upon activation of caspase-11, the cell succumbs to pyroptotic cell death, activates caspase-1, and releases proinflammatory mediators (Kang et al., 2000; Hagar et al., 2013; Kayagaki et al., 2011, 2013). Caspase-11–dependent release of proinflammatory mediators into the extracellular space during LPS-induced sepsis contributes to host mortality (Kayagaki et al., 2011, 2013; Hagar et al., 2013). In humans, caspase-4 and -5 are orthologues to caspase-11 (Shi et al., 2014; Casson et al., 2015), making this an intriguing cell death pathway to understand in the context of sepsis. Thus, an increased understanding of the regulation of caspase-4/5/11–dependent cell death pathway may lead to the identification of novel targets for the diagnosis and treatment of sepsis.

To identify new mediators of caspase-11–dependent cell death, we used a genome–wide CRISPR–Cas9 knockout screen in macrophages. The results of our screen highlight the complexity of caspase-11 gene expression. Specifically, we identified carboxypeptidase B1 (Cpb1), a complement–related protein, as a novel mediator of caspase-11 gene expression and subsequent caspase-11–dependent cell death in macrophages. Cpb1 modifies a cleavage product of C3, which binds to and activates C3aR, and then modulates innate immune signaling. Here, we elucidate the role of the Cpb1–C3–C3aR pathway in enhancing cell autonomous and non–cell autonomous inflammation by amplifying TLR4– and Ifnar–dependent expression of proinflammatory genes, including caspase-11, within macrophages. We find that TLR4– and Ifnar–signaling pathways, but not Ifngr signaling, converge at p38 MAPK signaling downstream of C3aR activation, highlighting the specificity of this amplification signaling pathway. We identified a role for C3aR, a key mediator of the Cpb1–C3–C3aR signaling pathway, in the early production of proinflammatory mediators, including caspase-11, in vivo and to the severity and outcome of disease in an endotoxemia model of severe sepsis. Furthermore, using a C3aR inhibitor, we show that C3aR may be a candidate for early therapeutic targeting during sepsis.

We demonstrate the clinical relevance of our findings by elucidating the role of C3aR in amplification of caspase-11 human orthologues, caspase-4 and -5, and release of proinflammatory cytokines in primary human macrophages during inflammation. Furthermore, using multicohort analysis, we find that c.3ar1 and caspase-5 are significantly up-regulated in human peripheral blood mononuclear cells (PBMCs) during sepsis, as compared with healthy controls. Thus, C3aR and caspase-5 transcripts may serve as biomarkers for diagnosing sepsis in humans, and this pathway may be targeted for the treatment of sepsis or septic shock.

Complement is known to play an important role in sepsis through multiple means (Flierl et al., 2008; Markiewski et al., 2008; Rittirsch et al., 2008), and we describe a novel mechanism in which complement amplifies proinflammatory signaling and thus contributes to poor sepsis outcomes. Our results describe the intersection of two known proinflammatory innate immune pathways, the caspase-11–dependent cell death pathway and the Cpb1–C3–C3aR complement signaling pathway, that contribute to inflammation and poor outcome during sepsis.

**RESULTS**

**CRISPR–Cas9 screen in RAW264.7 macrophages identifies mediators of caspase-11–dependent cell death**

Caspase-11–dependent cell death is triggered in murine primary BM-derived macrophages (BMDMs) by introducing LPS into the cytosol via cholera toxin B–subunit (CTB; Kayagaki et al., 2013). LPS and CTB treatment of WT BMDMs results in ~60% cell death within 16 h post-treatment (pt; Fig. 1 A). Similar to previous studies, this death is caspase-11 dependent and caspase-1 independent (Fig. 1 A; Hagar et al., 2013; Kayagaki et al., 2013). To create a genetically tractable model for caspase-11–dependent cell death, we recapitulated this cell death phenotype in a murine-transformed macrophage cell line, RAW264.7 (RAW). Treatment of WT RAW cells with LPS and CTB for 16 h results in death of ~80% of the cells, which is similar to WT BMDMs (Fig. 1 B). Additionally, the requirement of CTB for LPS-induced cell death can be bypassed by transfecting LPS into RAW cells, resulting in ~40% cell death 16 h pt, similar to BMDMs (Fig. 1 B; Hagar et al., 2013; Kayagaki et al., 2013). Together, these data demonstrate that RAW macrophages respond to intracellular LPS comparably to BMDMs.

To determine whether cell death caused by intracellular LPS was dependent on caspase-11, and not caspase-1, we disrupted caspase-11 and -1 using the CRISPR–Cas9 genome editing system (Cong et al., 2013; Storek et al., 2015). We found that intracellular LPS induced cell death primarily in a caspase-11–dependent, caspase-1–independent manner (Fig. 1 B). Important to note, caspase-1 is directly upstream of caspase-11 on Chromosome 9 in C57BL/6J mice, thus we checked if disruption of either of these genes affected the other (Kang et al., 2000). Disruption of caspase-11 did not affect the protein levels of caspase-1, and vice versa (unpublished data). We went on to complement the disrupted caspase-11 gene by expressing a WT copy of caspase-11 tagged at the C terminus with FLAG/HA under the pMSCV promoter. The complemented cell line restored the cell death phenotype to 50% of the WT RAW cell death (Fig. 1 B). Together, these data show that RAW cells are a genetically tractable model and can be used to study caspase-11–dependent cell death in macrophages.

Next, we constructed a CRISPR–Cas9 genome–wide knockout library in WT RAW cells to identify novel mediators of caspase-11–dependent cell death (Koike-Yusa et al., 2014). This library is a pool of 87,897 guide RNAs (gRNAs) against 19,150 mouse protein-coding genes expressed from lentiviral vectors (Koike-Yusa et al., 2014). We constructed WT RAW that constitutively express human codon–optimized Cas9 nuclease (hCas9) for genome editing (Fig. 1 C). The expression of hCas9 did not affect the cell death kine-
Figure 1. CRISPR-Cas9 screen identifies Cpb1 to be required for caspase-11 expression, activation, and cell death in macrophages. (A) BMDMs were treated with intracellular LPS via CTB for 16 h, and then cytotoxicity was measured. (B) RAW264.7 transformed murine macrophage cell line (RAW) was treated with CTB/LPS or transfected LPS for 16 h and cytotoxicity was measured. (C) Expression of humanized Cas9 (hCas9) was determined in WT RAW cells that were either untreated or transduced with a lentiviral construct that stably expresses hCas (WT-hCas9), or the same cells were treated with LPS/CTB for 16 h and cytotoxicity was measured. (D) A macrophage genetic screen identified KOs that confer resistance to intracellular LPS stimulation via 16 h treatment with CTB/LPS. Each plot represents a gene (x axis). Genes are ranked on the y axis according to the significance (-LogPvalue) of enrichment, which was calculated by an accumulated hypergeometric distribution function (König et al., 2007), in the CTB/LPS-treated library compared with the nonselected control population. The top 100 hits are highlighted in the extrapolated box. Blue genes, CTB receptor genes; purple genes, complement genes; red, yellow, and green, other hits followed up on. (E–I) WT and KO cell lines were treated with LPS/CTB or transfected with LPS for 16 h and cytotoxicity was measured, (I) with or without the Cpb-inhibitor (MGTA). (J) WT, Cpb1 KO, and Cpb1 KO cells complement with either Cpb1 (Cpb1 KO + Cpb1) or caspase-11 (Cpb1 KO + caspase-11).
ics in WT RAW cells after treatment with LPS and CTB (Fig. 1 C). Next, we transduced the WT-hCas9 cell line with lentiviral vectors created from the gRNA library, as previously described (Koike-Yusa et al., 2014). To identify genes required for caspase-11–dependent cell death, we induced cell death by treating the pooled mutant library with LPS and CTB for 16 h. We expected that surviving cells should have mutations in genes required for caspase-11–dependent cell death.

We calculated enrichment of genes (% counted in treated cells) [% counted in untreated cells]) and used these values along with the number of gRNAs per gene that came out of the screen to determine the P-value for each gene (Table S1; Koike-Yusa et al., 2014). As confirmation of our method, our top hit was B4galat1, which is a gene required for the production of the CTB receptor (GM1 sphingolipid; Fig. 1 D; Wolf et al., 2008; Papatheodorou et al., 2011; Chinnapen et al., 2012; Jobling et al., 2012). Although caspase-11 was not enriched in our screen, it is possible that the caspase-11 gRNAs present in the library were ineffective or lost during amplification of the library. To verify four of our top novel hits, we created knockout RAW cell lines using the gRNAs identified from the screen and treated them with CTB and LPS for 16 h. RAW cells deficient for three of these hits showed a cell death defect after 16 h of CTB and LPS treatment, whereas the Acd6 KO cell line displayed similar levels of cell death compared with WT RAW cells (Fig. 1 E). To ensure that these genes were required for caspase-11–dependent cell death, and not CTB-dependent delivery of LPS into the cytosol, we transfected LPS into each knockout cell line. While most of our knockout cell lines had decreased levels of cell death after transfection with LPS compared with WT cells, only the Cpb1KO cell line displayed significant defects after treatment with CTB and LPS, as well as LPS transfection (Fig. 1 E). Together, these data demonstrate that the CRI SPR-Cas9 genome-wide screening method in RAW macrophages is a useful tool to identify novel genes, such as Cpb1, involved in the caspase-11–dependent cell death pathway.

**Cpb1 is required for caspase-11 expression, activation, and cell death**

Our CRI SPR-Cas9 genome-wide cell death screen identified Cpb1 as a novel gene required for a caspase-11–dependent cell death pathway. To confirm the role of Cpb1 in cell death induced by cytosolic LPS, we created five independent Cpb1 knockout cell lines and found that each of these distinct mutants were ~50% defective for cell death 16 h pt with CTB and LPS (Fig. 1 F). We confirmed a significant reduction in cell death after 16-h treatment with intracellular LPS, via CTB or transfection, compared with WT RAW cells in one clone, Cpb1-10 (Fig. 1, G-H). We used a pan-carboxypeptidase inhibitor (2-mercaptomethyl-3-guaninodithioic propanoic acid [MGTA]) to assess the importance of Cpb1 enzymatic activity during intracellular LPS treatment. We found that during CTB/LPS treatment of macrophages, the presence of MGTA reduces caspase-11–dependent cell death in a dose-dependent manner (Fig. 1 D); thus, underlining the importance of the enzymatic activity of Cpb1 during caspase-11–dependent cell death. Importantly, the cell death defect in Cpb1 KO cells was rescued by expressing a WT copy of Cpb1 under a pMSCV promoter (Fig. 1 J).

We hypothesized that the requirement of Cpb1 was specific to caspase-11–dependent cell death, and not caspase-1–dependent cell death. To test this, we induced caspase-1–dependent cell death via treatment with LPS and nigericin for 9.5 h, and found that Casp11 KO and Cpb1 KO cells died at similar levels as WT cells; however, the Casp1 KO cells had a reduction in cell death after treatment (unpublished data). Collectively, these results indicate that Cpb1 contributes specifically to caspase-11–dependent cell death in macrophages.

Caspase-11 activation is a hallmark of caspase-11–dependent cell death (Zhang et al., 2013). Thus, we measured caspase-11 activation in WT and KO cell lines by detecting cleavage and release of the C-terminal p30 portion of full-length caspase-11 (pro-casp11) into the supernatant of activated and dying cells (Kang et al., 2000). 16 h pt of WT cells with CTB and LPS resulted in an increase of pro-casp11 and p30 into the supernatant (SN) as a result of caspase-11 activation and release of cytosolic contents upon cell death (Fig. 1 K). In concordance with our previous data, there were lower levels of pro-casp11 in the SN from Cpb1 KO cells compared with the WT cells after CTB and LPS treatment (Fig. 1 K). In addition, the caspase-11 p30 cleavage product was not detected in the SN from Cpb1 KO cells treated with LPS and CTB (Fig. 1 K). As expected, pro-casp11 and p30 were not detected in the SN from Casp11 KO cell line 16 h pt with LPS and CTB (Fig. 1 K). Interestingly, the level of pro-casp111 in the lysates of Cpb1 KO cells treated with LPS was markedly lower compared with the WT cells treated with LPS suggesting that Cpb1 may contribute to cell death by controlling the level of caspase-11 gene expression (Fig. 1 K). To test this notion, we expressed a WT copy of caspase-11 on an exogenous vector and measured cell death in response to LPS and CTB. Ectopic expression of caspase-11 in
Our data indicate that Cpb1 is acting upstream of caspase-11 gene expression and may be involved in amplification of the TLR4 signaling pathway after stimulation with LPS. We, and others, have shown previously that caspase-11 expression is dependent on MyD88 and TIR domains of TLR4 (Kayagaki et al., 2011; Broz et al., 2012; Rathinam et al., 2012). To analyze the contribution of Cpb1 to TLR4-dependent caspase-11 gene expression, we treated WT and Cpb1 KO cells with LPS for 2 h to initiate TLR4-dependent expression of proinflammatory genes and measured expression of caspase-11 by quantitative real-time PCR (qRT-PCR) to determine transcript levels. Similar to previous studies, the level of caspase-11 transcript in WT cells is significantly increased after 2-h treatment with extracellular LPS (Fig. 1 L). In contrast, the level of caspase-11 gene expression in the Cpb1 KO cell line did not increase after 2 h of extracellular LPS treatment (Fig. 1 L). Of note, caspase-1, which is not influenced by TLR4-dependent signaling, was unaffected in WT and Cpb1 KO cells (Fig. 1 L). Thus, our results indicate that Cpb1 is required for WT levels of caspase-11 expression, activation, and cell death in response to cytosolic LPS.

Our results indicate that Cpb1 somehow impacts TLR4-dependent expression of caspase-11 and perhaps the expression of additional proinflammatory genes. Il-6 and tnf transcripts were significantly reduced compared with WT RAW cells after 2-h LPS treatment, similar to Cpb1 KO cells (Fig. 2 A). In addition, the expression of il-6 and tnf transcripts were significantly reduced compared with WT cells, again mimicking the Cpb1 KO cells (Fig. 2 B). These data demonstrate that the Cpb1–C3–C3aR signaling pathway is required for TLR4-dependent up-regulation of proinflammatory transcripts downstream of LPS stimulation.

Because increased caspase-11 gene expression is required for caspase-11–dependent cell death, we measured cell death induced by intracellular LPS stimulation in C3aR KO and C3 KO cell lines. Cell death in C3aR KO and C3 KO cell lines was reduced by 50% compared with WT RAW cells 16 h pt with CTB and LPS (Fig. 2 E). C3- and C3aR-deficient BMDMs had significantly lower levels of cell death compared with WT RAW cells 16 h pt with CTB and LPS (Fig. 2 D). Together, these data show that the Cpb1–C3–C3aR complement pathway is required for TLR4-dependent expression of caspase-11 and subsequent caspase-11–dependent cell death. Thus, we reveal a novel contribution of the complement pathway to caspase-11–dependent gene expression and cell death.

We next verified that the Cpb1–C3–C3aR pathway is required for caspase-11–dependent cell death in murine primary BMDMs. BMDMs were generated from WT, caspase-11–deficient (Casp11−/−), C3aR-deficient (C3aR−/−), and C3–deficient (C3−/−) mice to assess caspase-11–dependent cell death. Similar to previous publications, >80% of the WT BMDM died by 16 h pt with LPS and CTB (Fig. 2 E). In contrast, treatment of Casp11−/− BMDMs with LPS and CTB resulted in background levels of cell death, ~20%, 16 h pt (Fig. 2 E). C3− and C3aR−deficient BMDMs had significantly lower levels of cell death compared with WT BMDMs after 16-h treatment with LPS and CTB (Fig. 2 E), suggesting that C3 and C3aR mediate caspase-11–dependent cell death in primary cells. Finally, to further test the role of C3aR in caspase-11–dependent cell death in BMDMs, C3aR–deficient signaling was blocked by adding the C3a receptor antagonist (C3aR-Ant). Treatment of WT BMDMs with C3aR-Ant resulted in a dramatic decrease in LPS-induced cell death (Fig. 2 E).

We hypothesize that C3aR and C3 are required for caspase-11–dependent cell death in BMDMs through the Cpb1–C3–C3aR pathway is required for TLR4–dependent expression of proinflammatory genes and caspase-11–dependent cell death.

Cpb1 is a peptidase that cleaves basic residues from the C terminus of intracellular and extracellular peptides (Moore and Benoiton, 1978; Leung et al., 2008). Murine Cpb1 is the orthologue to human CPB, which modifies C3a, a 77-aa anaphylatoxin generated by enzymatic cleavage of C3 during activation of the complement system (Leung et al., 2008). CPB cleaves the C-terminal arginine of C3a to create C3a-desArg (Moore and Benoiton, 1978; Leung et al., 2008). This modified molecule, C3a-desArg, engages the C3aR receptor, a complement receptor that belongs to the rhodopsin family of seven-transmembrane, G protein–coupled receptors expressed on both BM-derived myeloid and lymphoid cells (Crass et al., 1996; Martin et al., 1997; Zwirner et al., 1999). Activation of C3aR leads to modulation of innate immune responses during LPS stimulation and Gram-negative bacterial infections, including induction of proinflammatory cytokines IL-6 and TNF (Takabayashi et al., 1996; Mueller-Ortiz et al., 2006). C3aR activation has been shown to mediate expression of TLR4–dependent transcripts (Zhang et al., 2007). Thus, Cpb1 may modulate TLR4–dependent expression of proinflammatory cytokines through complement receptor C3aR (see also Fig. 7).

To interrogate this hypothesis, we disrupted C3aR and C3 in RAW macrophages using the CRISPR-Cas9 genome editing system (Fig. S1 B and C). We reasoned that if the Cpb1–C3–C3aR signaling pathway is required for up-regulation of caspase-11 transcripts, then all three of these genes should be necessary for TLR4–dependent expression of caspase-11. As predicted, the level of caspase-11 transcripts was significantly lower in C3aR KO and C3 KO cell lines, compared with WT RAW macrophages after 2-h LPS treatment, similar to Cpb1 KO cells (Fig. 2 A). In addition, the expression of il-6 and tnf transcripts were significantly reduced compared with WT cells, again mimicking the Cpb1 KO cells (Fig. 2 B). This data imply that Cpb1 is required for amplification of proinflammatory genes.
amplification of TLR4-dependent transcripts, as seen in RAW macrophages. Thus, we measured caspase-11, il-6, and tnf gene expression in WT, C3aR KO, and C3 KO RAW cell lines after LPS stimulation and found that C3aR KO and C3 KO BMDMs did not express these transcripts at WT levels (Fig. 2, F and G). The defect in expression of il-6 and tnf transcripts corresponded with a significant reduction in IL-6 and TNF cytokine release from C3aR KO BMDMs compared with the WT BMDMs (Fig. 2 H). Although the C3aR KO and C3 KO mice were generated in an Sv129 embryonic background these mice were thoroughly backcrossed and do not retain the known Sv129 5 base-pair deletion at the caspase-11 genetic locus (Fig. S2). These data demonstrate that the Cpb1–C3–C3aR pathway is required in transformed macrophages, as well as primary macrophages for expression and release of TLR4-dependent proinflammatory mediators, highlighting its importance for caspase-11–dependent cell death in response to intracellular LPS.

Cpb1–C3–C3aR pathway increases MAPK activity downstream of TLR4 and Ifnar activation in a cell autonomous and non–cell autonomous manner

Caspase-11 gene expression can be induced downstream of TLR4 activation, or interferon signaling pathways through Ifnar and Ifngr activation (Kayagaki et al., 2011; Broz et al., 2012; Rathinam et al., 2012). Although we have shown that the Cpb1–C3–C3aR pathway amplifies proinflammatory transcripts, including caspase-11, downstream of TLR4 activation, it is not known whether the Cpb1–C3–C3aR pathway directly modulates Ifnar or Ifngr signaling. To activate Ifnar signaling, primary macrophages were treated with IFN-β, and the levels of caspase-11 and NOS2, Ifnar-de-
pendent transcripts, were measured. As expected, there was an amplification of caspase-11 and NOS2 transcripts in WT BMDMs treated with IFN-β for 2 h (Fig. 3 A). In contrast, the levels of caspase-11 and NOS2 transcripts were significantly lower in the C3aR−/− and C3−/− macrophages treated with IFN-β for 2 h compared with WT BMDMs (Fig. 3 A). In addition, we activated BMDMs with IFN-γ and measured up-regulation of the IFN-γ-dependent genes caspase-11 and NOS2. Interestingly, WT, C3aR−/−, and C3−/− macrophages expressed caspase-11 and NOS2 transcripts at similar levels after 2 h of stimulation with IFN-γ (Fig. 3 B). Collectively, these data indicate that the Cpb1–C3–C3aR signaling pathway is important for amplification of Ifnar-dependent signaling, but not Ifngr-dependent signaling, during the first 2 h after cytokine stimulation. Surprisingly, this is the first demonstration of C3aR-dependent amplification of Ifnar-dependent signaling. Our results indicate that signaling through the Cpb1–C3–C3aR pathway amplifies TLR4-dependent signaling and type I interferon-stimulated Ifnar signaling in macrophages, but not Ifngr-dependent signaling (see also Fig. 7).

It has been described that C3aR activation can amplify MAPK signaling downstream of TLR4 stimulation (Zhang et al., 2007). Additionally, Ifnar signaling leads to downstream activation of MAPKs (Poovassery and Bishop, 2012). Thus, we hypothesize that Cpb1–C3–C3aR pathway amplification of TLR4- and Ifnar-dependent gene expression converges on MAPK signaling within the host cell. We measured phosphorylation of p38 MAP kinase as a read-out of MAPK family activity, to identify the level of MAP kinase activation in WT versus complement-deficient macrophages after various stimuli. After 2 h of treatment with LPS, p38 phosphorylation in WT BMDMs increases sixfold, whereas the C3aR−/− BMDMs show approximately twofold induction of p38 phosphorylation (Fig. 3 C). Additionally, when BMDMs are treated with IFN-β for 2 h, there is a twofold increase of p38 phosphorylation in WT cells compared with a less than onefold induction in C3aR−/− BMDMs. In congruence
with our hypothesis, p38 phosphorylation was not induced in IFN-γ-treated WT or C3aR−/− BMDMs (Fig. 3 C). These data indicate that C3aR activation influences MAPK signaling downstream of TLR4 and Ifnar activation, but not Ifnar activation, implicating p38 MAPK as a potential convergence of these signaling pathways (see also Fig. 7).

There are multiple G protein–coupled receptors that enhance MAPK activation through p38 in a cell autonomous and non–cell autonomous manner during inflammation (Yamauchi et al., 1997; Robinson and Dickenson, 2001; Kawli et al., 2010; Grimsey et al., 2015). Additionally, human CPB is found in high concentrations in serum (Leung et al., 2008; Chatterjee et al., 2009), C3 is quickly released from monocytes and macrophages (Goodrum, 1987), and C3aR is an extracellular receptor, suggesting that this pathway may have non–cell autonomous affects. We have shown thus far that Cpb1–C3–C3aR pathway is enhancing cell autonomous proinflammatory signaling; however, we hypothesize that the Cpb1–C3–C3aR pathway can also work in a non–cell autonomous manner. To test this, we treated WT, Cpb1KO, and C3aR KO RAW macrophages with LPS for 2 h and collected the supernatants. We then treated naive Cpb1 KO cells with the supernatants for 2 h and looked for expression of proinflammatory transcripts. When Cpb1 KO cells were treated with the conditioned WT or C3aR supernatants, both of which have functioning Cpb1 within the supernatants, caspase-11, IL-6, and TNF transcripts were significantly up-regulated compared with Cpb1 KO cells treated with conditioned supernatants from Cpb1 KO cells (Fig. 3 D). These data confirm that Cpb1–C3–C3aR pathway acts in a cell-autonomous and non–cell autonomous manner during inflammation in macrophages.

Together, our data suggests that the Cpb1–C3–C3aR pathway amplifies proinflammatory mediators by increasing MAPK signaling downstream of TLR4 and Ifnar stimulation and that the effect of this pathway on macrophages can manifest in a cell-autonomous and non–cell autonomous manner. This data, combined with our previous data showing that this amplification is important for induction of caspase-11 transcripts and caspase-11–dependent cell death, illuminates the potential importance of this proinflammatory amplification pathway during response to intracellular LPS during Gram-negative bacterial infections and sepsis.

**C3aR is required for severity of endotoxemia**

Caspase-11 promotes disease severity and reduces survival time during severe sepsis induced by LPS, or endotoxemia (Kayagaki et al., 2011, 2013; Hagar et al., 2013). This suggests that caspase-11–dependent cell death, during endotoxemia in mice, increases severity of disease and expedites mortality. We have shown here that the Cpb1–C3–C3aR pathway is important for caspase-11 induced gene expression and subsequent caspase-11–dependent cell death in vitro. We hypothesize that the Cpb1–C3–C3aR pathway contributes to the severity of endotoxemia by regulating the expression of proinflammatory mediators, such as caspase-11, in vivo. To interrogate this hypothesis, we established a mouse model in which mice receive an i.p. injection with a sublethal dose of LPS, followed by an i.p. injection of a lethal dose of LPS to induce endotoxemia. Proinflammatory gene expression in blood was measured at 2 h after the sublethal LPS injection. Disease severity was assessed after injection of the lethal pathogen.
LPS injection by measuring body temperature and weight loss every 2–4 h pt (Marshall et al., 2005; Gonnert et al., 2011; Gentile et al., 2014).

We found that 2 h after the primary sublethal dose of LPS, C3aR−/− mice had a significant defect in expression of caspase-11 in the blood, compared with WT mice (Fig. 5 A). Additionally, il-6 transcripts in the blood were significantly lower in C3aR−/− compared with WT mice (Fig. 5 B). WT mice injected with a sublethal dose of LPS and the C3aR inhibitor displayed a reduced level of caspase-11 and il-6 transcripts in the blood compared with mice that were not given the antagonist (Fig. 5, E and F). After the first injection (6 h), these same mice were injected with a lethal dose of LPS and C3aRi and weight and temperature were recorded to track endotoxemia severity. As seen in the C3aR−/− mice, mice treated with the C3aRi had significantly less weight loss (Fig. 5 G). However, the mice treated with C3aRi did not have a difference in temperature loss compared with untreated mice (Fig. 5 H). Notably, the levels of IL-6 detected in the blood of mice treated with C3aRi were significantly lower than control mice 2 h after injection of low dose LPS (Fig. 5 I). These data suggest C3aR as a potential therapeutic target for decreasing endotoxemia severity, and highlight a bifurcation in weight loss and temperature loss during sepsis that may be interesting to uncover in future experiments. Finally, we determined whether treatment of mice with C3aRi during endotoxemia could influence survival. We induced endotoxemia in WT mice, with and without C3aRi, and found that mice treated with C3aRi are partially protected from LPS-induced mortality (Fig. 5 J).

Together, these data suggest that C3aR, a key mediator in the Cpb1–C3–C3aR pathway, plays a role in early expression of inflammatory mediators in the blood during endotoxemia and contributes to endotoxemia severity and disease outcome.

C3aR contributes to enhanced inflammation in primary human macrophages

Caspase-4 and -5 are the potential human orthologues to murine caspase-11, and have been described to play a role in responding to LPS and Gram-negative bacterial pathogens in primary human monocyte–derived macrophages (MDMs; Casson et al., 2015). There is evidence that expression of caspase-4 and -5 is induced upon host cell exposure to LPS; however, the role of this induction in inflammation is not clear (Munday et al., 1995; Lin et al., 2000; Eckhart et al., 2006; Casson et al., 2015; Viganò et al., 2015). Additionally, it is not known what signaling pathways contribute to expression of these caspases downstream of TLR4. Considering our data presented thus far, we hypothesize that C3aR may be required for early induction of caspase-4 and -5 and subsequent inflammation. Thus, we first tested the early kinetics compared with WT mice 2–20 h after lethal dose (Fig. 5, C and D). Thus, a key regulator of the Cpb1–C3–C3aR amplification pathway, C3aR, is required for WT expression of proinflammatory mediators in the blood and contributes to the severity of pathologies during endotoxemia, highlighting the importance of this signaling pathway during acute severe sepsis in vivo.

Furthermore, we were interested to know if we could pharmacologically block C3aR activation and decrease the severity of pathologies in mice with endotoxemia. We used a selective nonpeptide antagonist of C3aR (C3aRi; SB290157), shown to be effective in vivo, to block C3aR activation in our mouse model (Ames et al., 2001). Mice injected with a sublethal dose of LPS and the C3aR inhibitor displayed a reduced level of caspase-11 and il-6 transcripts in the blood compared with mice that were not given the antagonist (Fig. 5, E and F). After the first injection (6 h), these same mice were injected with a lethal dose of LPS and C3aRi and weight and temperature were recorded to track endotoxemia severity. As seen in the C3aR−/− mice, mice treated with the C3aRi had significantly less weight loss (Fig. 5 G). However, the mice treated with C3aRi did not have a difference in temperature loss compared with untreated mice (Fig. 5 H). Notably, the levels of IL-6 detected in the blood of mice treated with C3aRi were significantly lower than control mice 2 h after injection of low dose LPS (Fig. 5 I). These data suggest C3aR as a potential therapeutic target for decreasing endotoxemia severity, and highlight a bifurcation in weight loss and temperature loss during sepsis that may be interesting to uncover in future experiments. Finally, we determined whether treatment of mice with C3aRi during endotoxemia could influence survival. We induced endotoxemia in WT mice, with and without C3aRi, and found that mice treated with C3aRi are partially protected from LPS-induced mortality (Fig. 5 J). Together, these data suggest that C3aR, a key mediator in the Cpb1–C3–C3aR pathway, plays a role in early expression of inflammatory mediators in the blood during endotoxemia and contributes to endotoxemia severity and disease outcome.
of caspase-4 and -5 expression in MDMs after treatment with LPS. We found that both pro-caspase-4 and -5 were induced after 3 h of stimulation compared with the untreated control (Ctrl; Fig. 6 A). Additionally, at 3 h pt we can detect higher levels of p20 fragment of caspase-5, a potential indicator of caspase-5 activation, in the LPS-treated samples compared with the Ctrl (Fig. 6 A). Thus, caspase-4 and -5 expression, and possibly caspase-5 activation, is induced by LPS treatment within 3 h in MDMs.

To elucidate if C3aR is involved in up-regulation of caspase-4 and -5, we treated MDMs with LPS, with and without the C3aR inhibitor (C3aRi). At 3 h pt, C3aRi-treated MDMs expressed lower levels of pro-caspase-4 and -5 (Fig. 6 B). Additionally, the caspase-5 p20 fragment was not detected after 3 h of LPS and C3aRi treatment in MDMs (Fig. 6 B). Furthermore, our results in mouse macrophages suggest that C3aR is amplifying proinflammatory mediators via increasing p38 MAPK activity downstream of TLR4 and Ifnar activation, but not Ifngr activation (Fig. 3, A–C). Considering these data, we propose that C3aR is modulating inflammatory signaling pathways in human macrophages similar to what was found in mouse cells. To test this, we treated MDMs with LPS, IFN-β, and IFN-γ for 3 h and looked at fold-change of p38-phosphorylation. As seen in the mouse mac-
phagocytes, in human MDMs p38 phosphorylation increases with LPS and IFN-β stimulation and does not increase in the IFN-γ or untreated cells (Fig. 6 C). Interestingly, when the MDMs were simultaneously treated with C3aRi and LPS or IFN-β, the induction of p38 phosphorylation was blocked (Fig. 6 C). Thus our data indicate that, in human and mouse macrophages, C3aR activation is required for induction of MAPK activity through phosphorylation of p38 downstream of LPS and IFN-β, but not IFN-γ.

We have shown that C3aR activation influences the induced expression of proinflammatory mediators in primary mouse macrophages. Thus, we hypothesize that blocking C3aR activation will reduce secretion of IL-6 and TNF in MDMs after stimulation by LPS. After 3 h of LPS treatment, both IL-6 and TNF were released at high levels from human MDMs and C3aRi significantly inhibited release of both cytokines in a dose-dependent manner (Fig. 6 D). Thus, these data identify C3aR as an early mediator of caspase-4 and -5 expression, MAPK activity, and proinflammatory cytokine release in primary human macrophages. However, it is still unknown if C3aR or caspase-4 and -5 are involved in human sepsis.

To study whether these genes may hold clinical relevance, we applied a previously described multicohort analysis framework to compare gene expression data from PBMCs from healthy controls versus patients with severe infections or sepsis (Khatri et al., 2013; Sweeney et al., 2015). We found that across eight cohorts that matched inclusion criteria (Regunathan et al., 2005; Ramilo et al., 2007; Chaussabel et al., 2008; Ardura et al., 2009; Ioannidis et al., 2012; Severino et al., 2014; Brand et al., 2015), the expression of caspase-5 was significantly higher in adults experiencing sepsis versus healthy donors (Fig. 6 E), suggesting a potential role for caspase-5 in human sepsis. There was no significant change in the expression of caspase-4 in septic patients (unpublished data). Thus, these data find a bifurcation in the induction of caspase-4 and -5 transcripts, highlighting a potential evolutionary divergence in requirement for these caspases during severe sepsis in humans. Notably, we also found that C3aR is expressed at significantly higher levels in PBMCs in patients with sepsis (Fig. 6 E), suggesting an important role for both caspase-5 and C3aR–signaling in clinical sepsis. Together, these data elucidate the role of C3aR as a mediator of inflammation in primary human macrophages and demonstrated increased expression of C3aR and caspase-5 transcripts in the blood, highlighting the possibility of using these transcripts as diagnostic markers of severe septic patients.
The multifaceted inflammatory response during sepsis has made the contribution of specific proinflammatory pathways difficult to delineate; however, it is known that caspase-11–dependent cell death contributes to poor sepsis outcomes in model organisms (Kayagaki et al., 2011, 2013; Hagar et al., 2013). Considering the importance of this cell death pathway in disease severity, we used the CRISPR-Cas9 genome editing system to create a genome-wide unbiased screen in macrophages to look for unique mediators of caspase-11–dependent cell death. Using this screen, we identified Cpb1 as a novel mediator of caspase-11 expression and subsequent caspase-11–dependent cell death in macrophages (Fig. 1). Cpb1 is a protein that modifies C3a, an anaphylatoxin product from cleaved complement protein C3, which binds and activates C3aR to modulate immune responses (Takabayashi et al., 1996; Mueller-Ortiz et al., 2006; Leung et al., 2008; Fig. 7). Disruption of Cpb1, C3, and C3aR led to a decrease in expression of caspase-11–dependent cell death (Fig. 2, C and F). Thus, we have elucidated complement as a novel mediator of caspase-11–dependent cell death, through the Cpb1–C3–C3aR signaling pathway.

Expression and activation of caspase-11 is important for cell death induced by Gram-negative bacterial infections, and also acts to exacerbate pathologies during endotoxin-induced sepsis (Broz and Monack, 2011; Kayagaki et al., 2011, 2013, 2015; Aachoui et al., 2013; Hagar et al., 2013). We find that Cpb1–C3–C3aR amplification pathway is important for responding to Gram-negative bacterial pathogens by showing the requirement for Cpb1, C3, and C3aR for caspase-11–dependent cell death during S. Typhimurium and S. flexneri infection (Fig. 4, A–C). Furthermore, in a model of severe endotoxin-induced sepsis, C3aR−/− mice had lower levels of caspase-11 and il-6 transcripts in the blood and moderate pathologies compared with WT mice (Fig. 5, A–D). We went on to show that inactivation of C3aR with a small nonpeptide C3aR inhibitor (C3aRi) reduces levels of caspase-11 and il-6 transcripts in the blood, IL-6 cytokines levels in the blood, weight loss during severe sepsis, and increased survival, suggesting C3aR may be a useful therapeutic target for mediating inflammation during the early stages of sepsis which may influence disease outcome (Fig. 5, E–J).

DISCUSSION

The multifaceted inflammatory response during sepsis has made the contribution of specific proinflammatory pathways difficult to delineate; however, it is known that caspase-11–dependent cell death contributes to poor sepsis outcomes in model organisms (Kayagaki et al., 2011, 2013; Hagar et al., 2013). Considering the importance of this cell death pathway in disease severity, we used the CRISPR-Cas9 genome editing system to create a genome-wide unbiased screen in macrophages to look for unique mediators of caspase-11–dependent cell death. Using this screen, we identified Cpb1 as a novel mediator of caspase-11 expression and subsequent caspase-11–dependent cell death in macrophages (Fig. 1). Cpb1 is a protein that modifies C3a, an anaphylatoxin product from cleaved complement protein C3, which binds and activates C3aR to modulate immune responses (Takabayashi et al., 1996; Mueller-Ortiz et al., 2006; Leung et al., 2008; Fig. 7). Disruption of Cpb1, C3, and C3aR led to a decrease in expression of caspase-11–dependent cell death (Fig. 2, C and F). Thus, we have elucidated complement as a novel mediator of caspase-11–dependent cell death, through the Cpb1–C3–C3aR signaling pathway.

Expression and activation of caspase-11 is important for cell death induced by Gram-negative bacterial infections, and also acts to exacerbate pathologies during endotoxin-induced sepsis (Broz and Monack, 2011; Kayagaki et al., 2011, 2013, 2015; Aachoui et al., 2013; Hagar et al., 2013). We find that Cpb1–C3–C3aR amplification pathway is important for responding to Gram-negative bacterial pathogens by showing the requirement for Cpb1, C3, and C3aR for caspase-11–dependent cell death during S. Typhimurium and S. flexneri infection (Fig. 4, A–C). Furthermore, in a model of severe endotoxin-induced sepsis, C3aR−/− mice had lower levels of caspase-11 and il-6 transcripts in the blood and moderate pathologies compared with WT mice (Fig. 5, A–D). We went on to show that inactivation of C3aR with a small nonpeptide C3aR inhibitor (C3aRi) reduces levels of caspase-11 and il-6 transcripts in the blood, IL-6 cytokines levels in the blood, weight loss during severe sepsis, and increased survival, suggesting C3aR may be a useful therapeutic target for mediating inflammation during the early stages of sepsis which may influence disease outcome (Fig. 5, E–J).
To understand the clinical relevance of our findings, we looked at the role of C3aR during inflammation in primary human macrophages. We found C3aR plays an integral role in the expression of caspase-11 human orthologues, caspase-4 and -5, and influences p38 MAPK activity downstream of TLR4- and Ifnar-activation, but not Ifngr activation (Fig. 6, A–C). The reduction inflammatory transcripts were reflected in a reduction of proinflammatory cytokine release when cells were treated with C3aRi (Fig. 6 D). Furthermore, we found, by multitohor gene expression analysis, that a caspase-11 orthologue, caspase-5, and c3aR transcripts are up-regulated in PBMCs in clinical sepsis compared with healthy controls, implicating this signaling pathway in humans experiencing sepsis (Fig. 6 E). Together, these data demonstrate that the Cpb1–C3–C3aR signaling pathway as an important mediator of caspase-11–dependent cell death, which is important for the response to Gram-negative bacteria and for severity of pathologies during sepsis. Additionally, this pathway may be playing a role in human sepsis.

Within the Cpb1–C3–C3aR signaling pathway, C3 must be converted into its cleaved product, anaphylatoxin C3a, and then modified by Cpb1 to activate C3aR signaling. Thus, supplementing Cpb1 KO cells with C3 should not be able to complement the Cpb1 KO cell death defect. In agreement with this hypothesis, transfection of recombinant C3 into macrophages during stimulation with intracellular LPS does not rescue the Cpb1 KO cell death phenotype (unpublished data). These preliminary results further suggest that the enzymatic activity of Cpb1 is required for this signaling pathway to amplify caspase-11–dependent cell death during intracellular LPS stimulation. Future biochemical assays will be essential in following up on this hypothesis.

Additionally, as mentioned previously, Cpb1 works by cleaving the C terminus basic residues (arginine [Arg] and lysine [Lys]) from various peptides, including the anaphylatoxin C3a (Bokisch and Müller-Eberhard, 1970; Matthews et al., 2004). It is known that an increase in free Arg can induce iNOS production in macrophages (Moncada and Higgs, 1991; Bogle et al., 1992; Xia and Zweier, 1997; Lee et al., 2003). Increased iNOS can play a very important role in worsening sepsis outcome and may play a role in induction of caspase-11–dependent cell death (Lupfer et al., 2014). Thus, it is possible that Cpb1 may be contributing to caspase-11–dependent cell death via induction of iNOS. However, when we stimulate WT and iNOS-deficient (iNOS−/−) BMDMs with intracellular LPS, there is no difference in cell death outcome (unpublished data). Accordingly, iNOS is not contributing to caspase-11–dependent cell death in macrophages; therefore, we conclude the contribution of an increase in free Arg by Cpb1 is not playing a role in our model.

Our findings support recently published data demonstrating that mice lacking Cpb2, a murine Cpb1 parologue, had significantly improved survival during polymicrobial sepsis (Shao et al., 2015). Shao et al. (2015) show that mice that lack Cpb2 had less severe pathologies after polymicrobial sepsis was induced by cecal ligation and puncture (CLP) and this was attributed to signaling through another complement receptor, C5aR. Furthermore, loss of Cpb2 is protective during E. coli–induced sepsis, similar to results seen in caspase-11–deficient mice treated with E. coli LPS (Renckens et al., 2005; Kayagaki et al., 2013). We hypothesize that Cpb2 may be playing a redundant role in amplification of proinflammatory transcripts, including caspase-11, and subsequent caspase-11–dependent cell death during sepsis, perhaps through C5aR.

It is notable that we show here that the Cpb1–C3–C3aR complement signaling pathway is acting as an amplification system to enhance cell autonomous and non–cell autonomous TLR4- and Ifnar-dependent signaling required for up-regulation of proinflammatory transcripts, including caspase-11 (Fig. 7). Amplification of TLR signaling by C3aR has been noted previously (Zhang et al., 2007); however, this is the first time that C3aR has been described to affect Ifnar signaling, and these data suggest that signaling downstream of this receptor may be more pleiotropic than previously presumed. Notably, we find C3aR is modulating p38 MAPK activity downstream of TLR4 and Ifnar, but not Ifngr, activation. Our data suggests that C3aR directly acts on p38 to induce activity, or another protein downstream of TLR and Ifnar, but upstream of p38. It will be interesting to elucidate the mechanism by which C3aR signaling modifies these signaling pathways, and if there other signaling pathways that are affected by C3aR activation during inflammation.

In addition, our data suggest that early signaling pathways may provide a potential therapeutic target during sepsis. In congruence with our findings, previous studies have found a close relationship between elevated plasma levels of C3a-desArg in patients with septic shock, and increased risk of developing adult respiratory distress syndrome or multiple organ failure, further implicating the Cpb1–C3–C3aR signaling pathway in human disease (Heideman and Hugli, 1984; Bengtson and Heideman, 1988; Heideman et al., 1988; Hack et al., 1989). Because caspase-5 and C3aR gene expression is induced in PBMCs from people with sepsis, it suggests that they may have a role in disease progression.

Our findings identify complement as a key pathway for amplification of proinflammatory cytokine production and caspase-11–dependent cell death and suggest a novel role for complement during bacterial infection and sepsis. Furthermore, we provide evidence that this complement pathway may be important during sepsis in human patients. Considering the compounding difficulty of diagnosing and treating sepsis due to overlapping proinflammatory pathways contributing to disease, our findings suggest that the Cpb1–C3–C3aR pathway could serve as a novel diagnostic and therapeutic target during early stage sepsis.

**MATERIALS AND METHODS**

**Cell culture**

BMDMs were isolated from the femurs of mice. C3−/− and C3aR−/− BMDMs were generously provided by Beth Stevens...
(Harvard Medical School, Boston, MA) and Rick Wetsel (University of Texas Medical School, Galveston, TX), respectively. BM cells were plated into sterile Petri dishes and incubated in DMEM supplemented with 10% FBS and 10% macrophage colony-stimulating factor (M-CSF)–conditioned medium (collected from M-CSF-producing NIH 3T3 cells). BMDMs were incubated at 37°C with 5% CO₂ and harvested after 6 d.

RAW264.7 macrophages and constructed KOs were cultured as previously described (Storek et al., 2015). 293T cells were grown in DMEM + 10% heat-inactivated FBS. All cells were incubated at 37°C with 5% CO₂.

RAW264.7 KO cell lines and complementation

All RAW264.7 KO cell lines were created using the CRI SPR/Cas9 system (Cong et al., 2013). Target gRNA sequences were generated using CRISPR Design and are listed in Table S2. The target gRNAs were then cloned into pX458 following a previously published protocol (Cong et al., 2013). A total of 10⁶ RAW264.7 macrophages were transfected with 3 µg pX458 in a 6-well tissue culture treated plate with 6 µl Fugene (Promega). 48 h pt, macrophages were single-cell sorted into 96-well tissue culture–treated plates with 200 µl of DMEM + 10% FBS. After 2 wk of incubation, gDNA from macrophage colonies was purified using QIAamp DNA mini kit (QIAGEN). The targeted DNA sequence was then amplified and sequenced (Elim Biopharm) with primers (Table S2).

Retroviral constructs were transduced into RAW264.7 macrophages using vesicular stomatitis pseudotyped virus packaged in 293T cells and selected for 48 h with 5 µg/ml puromycin (InvivoGen). Caspase-11 and Cpb1 were cloned in-frame into pMSCV-FLAG-HA-IRES-Puro using Gateway Cloning, as previously described (Storek et al., 2015).

Cell treatments and LDH assays

For cytotoxicity assays, RAW264.7 macrophages and BMDMs were plated in 96-well tissue culture treated plates at 50,000 cells per well. When specified, macrophages were treated with 20 µg/ml Cholera toxin B subunit (CTB; List Biological Laboratories) and 20 µg/ml ultra-pure LPS (E. coli O111:B4; InvivoGen), or 0.5 µl per well Fugene and 20 µg/ml ultra-pure LPS and/or recombinant mouse C3 (Abnova) in serum-free phenol-red-free OptiMem (11058–021; BioLegend) diluted 1:1,000, rabbit anti–mouse caspase-11 (17D9; Sigma-Aldrich) at 1:500, rabbit anti–mouse phospho-p38 (9211; Cell Signaling Technology) and β-actin (Sigma-Aldrich) diluted 1:2,000. Human Western blots were performed with rabbit anti–human caspase-4 (4450; Cell Signaling Technology) and caspase-5 (46680; Cell Signaling Technology) diluted 1:1,000, and rabbit anti–mouse phospho-p38 (9211; Cell Signaling Technology). Quantification of induction of relative protein expression was measured using Image Lab 5.2.1, as-compared with untreated.

Real-time PCR

Macrophages were treated with 0.1 µg/ml ultra-pure LPS or 100 U/ml recombinant mouse IFN-β or IFN-γ (BioLegend) for 2 h and macrophages were lysed and homogenized in 250 µl TRIzol reagent (MRC). For in vitro samples, RNA was isolated using the RNeasy Mini kit (QIAGEN). cDNA was synthesized from RNA samples using SuperScript III First-Strand synthesis system (Invitrogen). Gene-specific primers (Table S3) were used to amplify transcripts using FastStart Universal SYBR Green Master (Rox; Roche).

Immunoblot analysis

Macrophages were seeded at 10⁶ cells in 6-well tissue culture treated wells and treated as described for 2–16 h. At specified time points, the supernatant was collected and precipitated with 10% trichloroacetic acid (TCA) overnight on ice. Precipitated proteins were pelleted at 20,000 g for 30 min at 4°C, washed with ice-cold acetone, air-dried, resuspended in SDS-PAGE sample buffer, and heated to 95°C for 10 min. In parallel, the macrophage monolayer was collected and lysed using RIPA buffer for 30 min on ice with agitation. Protein from 5 × 10⁶ cells was loaded per well of a Criterion TGX AnykD Gel (Bio-Rad Laboratories). Mouse Western blots were performed with rabbit anti–mouse caspase-1 (Santa Cruz Biotechnology, Inc.) diluted 1:1,000, rat anti–mouse caspase-11 (17D9; Sigma-Aldrich) at 1:500, rabbit anti–mouse phospho-p38 (9211; Cell Signaling Technology) and β-actin (Sigma-Aldrich) diluted 1:2,000. Human Western blots were performed with rabbit anti–human caspase-4 (4450; Cell Signaling Technology) and caspase-5 (46680; Cell Signaling Technology) diluted 1:1,000, and rabbit anti–mouse phospho-p38 (9211; Cell Signaling Technology). Quantification of induction of relative protein expression was measured using Image Lab 5.2.1, as compared with untreated.

RAW264.7 CRISPR-Cas9 genome wide library

The genome-wide mouse lentiviral CRISPR gRNA pooled library (#50947; Addgene) from K. Yusa (Koike-Yusa et al., 2014) was used to construct this library. The gRNA library was amplified using the available library amplification protocol, by K. Yusa (Addgene), via the on-plate culture method (Koike-Yusa et al., 2014). The library was then transfected into 293T cells. To maintain 1,000× library, we transfected 5× T-175 tissue culture treated flasks (Falcon) at 11 × 10⁶ cells per flask. For next seeded 50× T-175 culture treated flasks with RAW 264.7 cells constitutively expressing hCas9 at 5 × 10⁶ cells/flask to maintain >1,000× coverage of the gRNA library. We transduced these cells at an MOI of 0.3 (Koike-Yusa et al., 2014) with filtered viral supernatants with 8 µg/ml of protamine sulfate. After 5 d of incubation, the transduced RAW cells were treated with 5 µg/ml of puromycin for selection. 3 d after puromycin treatment, the raw cells were cultured as previously described (Storek et al., 2015). After 11 d after transduction, the RAW cells were pooled, counted, and frozen back at 10 × 10⁶ cells/vial in 100% FBS.

For our screen, three vials of CRISPR/Cas9 gRNA library RAW cells were thawed and seeded into three T-175 flasks. One flask was used as an untreated control, and the other two were used as two separate screens. After 24 h of incubation, the media was removed and replaced by serum-free phenol-red-free OptiMem with and without CTB and LPS (at 4 µg per 5 × 10⁶ cells of each). After 16 h of treatment, media was...
replaced by fresh media and cells were grown for 6 d, media was replaced again and grown for an additional 3 d. At this point, cells were collected for all three conditions and gDNA was isolated using QiaAMP DNA mini kit. The amount of input gDNA for each sample was calculated to achieve 1,000× coverage of the gRNA library (Koike-Yusa et al., 2014). Dual amplification of the gRNA from the lentiviral backbone and then to add index adaptors (P5/P7) for MiSeq was used to create an amplicon library, as described previously (Koike-Yusa et al., 2014). A unique primer was used (5′-TCTTCCGAT CTctctgtgaaaggagcgaacG-3′) for MiSeq sequencing.

Genome-wide screen bioinformatic and statistical analysis

A hypergeometric P-value (HGPvalue) calculation was used for genome–wide screen enrichment statistical analysis. All genes listed above P ≤ 0.001 were retained (Table S1). The R version of this code was used and written by Y. Zhou and B. Zhou (Novartis), as previously described (König et al., 2007). All other statistical analysis was done using Prism 6.0 (GraphPad Software). The statistical significance was determined by the Student’s t test.

Bacterial cultures and infections

Bacterial strains include WT S. Typhimurium SL1344, SL1344 ΔorgA/fliC mutant, and WT S. flexneri M90T. Infections for genome-wide screen enrichment statistical analysis. All genes listed above P ≤ 0.001 were retained (Table S1). The R version of this code was used and written by Y. Zhou and B. Zhou (Novartis), as previously described (König et al., 2007). All other statistical analysis was done using Prism 6.0 (GraphPad Software). The statistical significance was determined by the Student’s t test.

Bacterial cultures and infections

Bacterial strains include WT S. Typhimurium SL1344, SL1344 ΔorgA/fliC mutant, and WT S. flexneri M90T. Infections for both RAW cells and BMDMs were conducted as described previously for BMDMs (Broz and Monack, 2011; Meunier et al., 2014; Kayagaki et al., 2015).

Mice and sepsis mouse model

Mice between 5–7 wk were used for in vivo experiments comparing BALBc mice (000651; The Jackson Laboratory) and C3ar1tm1Cge knock-out mice (C.129S4-C3ar1tm1cge/J; The Jackson Laboratory). Mice between 5–7 wk were used for in vivo experiments comparing BALBc mice (000651; The Jackson Laboratory) and C3ar1tm1Cge knock-out mice (C.129S4-C3ar1tm1cge/J; The Jackson Laboratory). All mouse studies were approved by the institutional animal care and use committees of Stanford University.

In mice tracked for temperature and weight, 1 wk before sepsis, mice were anesthetized locally with 1% lidocaine (4 mg/kg) on the right side hind–back using a 0.5 ml syringe. After 15 min, electronic temperature and ID transponders were implanted subcutaneously in the same right side hind–back region (IPTT-300 transponders; Bio Medic Data System, Inc.) and left to recover for 1 wk. Next, mice were either treated with 200 µl of PBS or LPS (4 mg/kg) via i.p. injection. 2 h pt, 10 µl of blood was collected via tail snip into 150 µl of RNALater (Ambion) and frozen at −80°C. RNA isolation and subsequent qRT-PCR was performed as previously described in our Materials and methods. At 6 h pt, mice were injected with a lethal dose of LPS (54 mg/kg) and pathologies were recorded for every 2 h for 20 h (weight and temperature). If the C3aR inhibitor (C3aRi; SB290157; Santa Cruz Biotechnology, Inc.) was used, it was injected at 30 mg/kg with LPS in PBS.

Isolating human PBMCs

Blood samples from healthy donors were obtained with informed consent and collected by research ethics committee (approved eProtocol; Minimal Risk Research Related Activities at Stanford Blood Center; SQL 79075). Human primary monocyte-derived macrophages (MDM) were prepared by adherence from whole-blood buffy fractions from healthy donors. Primary monocytes were cultured in RPMI 1640 with 10% FBS and treated with 30 ng/ml human M-CSF for 6 d. For all assays, 7 d after culture, MDMs were plated at 50,000 cells/well in a 96-well plate and assayed for cytokine release, or plated 1 million cells/well in a 6-well plate and assayed for protein expression level as described above.

Multicohort analysis

Multicohort analysis was performed as previously described (Khatri et al., 2013; Sweeney et al., 2015). In brief, a systematic search was performed in the National Institutes of Health Gene Expression Omnibus for datasets matching the terms: PBMC, sepsis, SIRS, infection, ICU, bacter[wildcard], acute. We retained clinical datasets that studied severe infections, and excluded datasets that included any ex vivo treatment of cells before microarray profiling, arriving at the final seven datasets (Table S1). GSE16129 contained two microarray types, which are treated as two separate cohorts, as previously described (Sweeney et al., 2015).

Online supplemental material

Fig. S1 showselectropherograms depicting the biallelic mutations for CRISPR–Cas9 knock–out RAW cell lines Cbp1KO, C3aRKO, and C3KO. Fig. S2 shows alignments of caspase-11 genes. Table S1 is a list of the top 100 enriched hits in the CRI SPR–Cas9 screen. Table S2 lists the gRNAs for each CR1 SPR–Cas9 knock–out cell line. Table S3 lists the sequences for each set of primers used in qRT-PCR. Table S4 provides information on the cohorts used in our multi–cohort analysis.

ACKNOWLEDGMENTS

We want to thank Sarah Ewald and Kelly Storek for helpful protocols and reagents, and Katie Cumnock for invaluable help with our mouse model. Additionally, we would like to thank Soyon Hung (Beth Steven’s laboratory, Harvard University, Boston, MA) and Stacey Mueller-Ortiz (Rick Wetsel’s laboratory, UT Houston, Houston, TX) for C3aR KO and C3KO mice, respectively. We would like to thank Aachoui, Y., I.A. Leaf, J.A. Hagar, M.F. Fontana, C.G. Campos, D.E. Zak, M.H. Settmacher, A. Klos, K.F. Erhard, R.D. Cousins, et al. 2001. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor

REFERENCES


